Published in World J Cardiol on May 26, 2014
Vascular calcification: When should we interfere in chronic kidney disease patients and how? World J Nephrol (2016) 0.78
Erectile dysfunction in chronic kidney disease: From pathophysiology to management. World J Nephrol (2015) 0.77
Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis (1998) 10.70
1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest (2002) 9.50
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int (2002) 9.29
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med (2012) 8.88
Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med (2000) 8.47
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int (2006) 6.61
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med (2004) 6.52
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int (2007) 6.34
Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant (2003) 6.15
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med (2008) 4.98
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol (2010) 4.59
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation (2006) 3.99
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet (2003) 3.70
Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int (2006) 3.63
Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int (2006) 3.36
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int (2007) 3.34
The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant (2010) 3.10
Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation (2012) 3.07
Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant (2004) 3.06
Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol (2005) 3.02
Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation (1999) 2.95
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun (2001) 2.63
Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int (2009) 2.60
Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol (2002) 2.58
Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res (2000) 2.50
Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol (2008) 2.47
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis (2013) 2.27
Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis (2011) 2.25
Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int (2004) 2.25
Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. Nephrol Dial Transplant (2006) 2.20
Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int (2007) 2.15
Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int (2009) 2.10
Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int (2002) 2.03
Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant (2011) 2.02
Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int (2008) 2.00
Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol (2013) 1.97
Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int (2006) 1.95
Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant (2010) 1.83
Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int (2012) 1.82
Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78
Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients. Am J Kidney Dis (2011) 1.74
Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis (2011) 1.69
Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int (2013) 1.67
Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int (2013) 1.66
Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int (2013) 1.66
Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis (1999) 1.63
Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res (2013) 1.61
Gla-containing proteins of bone. Connect Tissue Res (1989) 1.56
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int (2003) 1.53
Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int (2013) 1.47
Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation (2013) 1.47
Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int (2008) 1.46
Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant (2013) 1.45
High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis (2008) 1.40
The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant (2008) 1.39
Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol (2012) 1.38
Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol (2008) 1.35
Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol (2011) 1.29
Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res (2007) 1.23
Vitamin K nutrition, metabolism, and requirements: current concepts and future research. Adv Nutr (2012) 1.22
Thiosulfate reduces calcium phosphate nephrolithiasis. J Am Soc Nephrol (2009) 1.21
A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis (2009) 1.21
Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol (2007) 1.19
The phosphate binder equivalent dose. Semin Dial (2011) 1.19
Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol (2013) 1.17
Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension (2010) 1.14
Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant (2011) 1.12
Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant (2013) 1.11
Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification. Clin Nephrol (2004) 1.10
Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant (2012) 1.10
Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant (2004) 1.09
Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol (2012) 1.09
Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol (2012) 1.08
Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis (2004) 1.08
Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. Int J Nephrol Renovasc Dis (2013) 1.07
Intraperitoneal sodium thiosulfate for the treatment of calciphylaxis. Ren Fail (2006) 1.06
Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodial Int (2009) 1.06
Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol (2012) 1.05
Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol (2013) 1.02
Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis (2006) 1.02
Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton) (2011) 1.00
Vitamin K intake and status are low in hemodialysis patients. Kidney Int (2012) 0.99
Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant (2010) 0.97
Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int (2013) 0.96
Association of warfarin use with valvular and vascular calcification: a review. Clin Cardiol (2011) 0.95
Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol (2009) 0.95
No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int (2011) 0.95
Changes of coronary calcification after kidney transplantation. Am J Kidney Dis (2006) 0.92
Low magnesium and atherosclerosis: an evidence-based link. Mol Aspects Med (2003) 0.91
Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis (2010) 0.91
Evolution of coronary artery calcifications following kidney transplantation: relationship with osteoprotegerin levels. Am J Transplant (2009) 0.89
Sodium thiosulfate treatment of tumoral calcinosis in patients with end-stage renal disease. Ren Fail (1990) 0.88